<p>Researcher from Queen&#039;s University, Belfast open a mystery over drug used in cardiovascular disorders and defines dug used in cardiovascular disorder may treat diabetic blindness too.</p><p>WHO reported 422 million patients with diabetes globally and loss of vision or blindness is one of the most common problem in diabetic patients. Researcher from Queen&#039;s University in collaboration with GlaxoSmithKline done this research and found that generally used cardiovascular drug named Darapladib may reduce blindness in diabetic patients when used in the form of tablets.<br /><br /><a href="http://www.srlchem.com/" target="_blank" rel="noopener noreferrer"><img src="http://www.microbiozindia.com/images/ASX.png" alt="" /></a></p><p>With our study, we show that a blood lipid produced by Lp-PLA2 constitutes a novel trigger factor in diabetic macular edema and that use of Darapladib may not only constitute a cost-effective alternative to current DMO treatments, but has the potential to be effective for patients that currently do not respond to standard treatment.&amp;quot; Said, Dr Patric Turowski from the UCL Institute of Ophthalmology.</p><p><strong>Story source:</strong> Queen&#039;s University</p><p>Journal References:</p><p>Paul Canning, Bridget-Ann Kenny, Vivien Price, Josephine Glenn, Mosharraf H. Sarker, Natalie Hudson, Martin Brandt, Francisco J. Lopez, David Gale, Philip J. Luthert, Peter Adamson, Patric Turowski, Alan W. Stitt. Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. Proceedings of the National Academy of Sciences, 2016; 201514213 DOI: 10.1073/pnas.1514213113</p>